CGT

7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the Clinic

Retrieved on: 
Lunedì, Giugno 3, 2024
Research institute, Hematopoietic stem cell transplantation, UCB, DSM-IV codes, B cell, Bone marrow, Patient, CCBC, STTR, The Texas Heart Institute, Cancer prevention, Medical director, ALL, AML, Immune system, THI, Catalysis, Risk, Hospital, Lung, Blood, Research, CD34, CGT, Radiation, Infection, CRISPR

This grant will allow 7 Hills to advance 7HP935, the Company’s lead first-in-class small molecule to augment CGT, through a Phase I clinical trial.

Key Points: 
  • This grant will allow 7 Hills to advance 7HP935, the Company’s lead first-in-class small molecule to augment CGT, through a Phase I clinical trial.
  • 7 Hills Pharma aims to increase clinical utilization of cord blood resources and improve patient access to life-saving HSCT.
  • Bone marrow is the tissue that generates red blood cells, platelets, and the white blood cells that comprise the immune system.
  • Dr. Peter Vanderslice is a co-founder of 7 Hills Pharma and a pioneer of small molecule integrin activation.

Ori Biotech and CTMC Present Scientific Data for New IRO® Platform at ISCT 2024

Retrieved on: 
Lunedì, Giugno 3, 2024
Type D, Automation, ISCT, Drug development, GMP, International Society, IRO, Ori, CTMC, CGT, Resilience, FDA, Partnership, COGS, Cell, Conference, Pharmaceutical industry

Ori Biotech CEO Jason C. Foster and CTMC Co-Founder + CEO Jason Bock revealed the companies’ findings at the 30th annual International Society for Cell & Gene Therapy (ISCT) Conference in Vancouver, Canada.

Key Points: 
  • Ori Biotech CEO Jason C. Foster and CTMC Co-Founder + CEO Jason Bock revealed the companies’ findings at the 30th annual International Society for Cell & Gene Therapy (ISCT) Conference in Vancouver, Canada.
  • Manufacturing remains a critical barrier to scaling cell and gene therapies, thus far, limiting the clinical and commercial impact of this life-saving new class of therapies.
  • Through their collaboration , Ori and CTMC evaluated the IRO platform's capabilities to manufacture a clinical-stage CAR-T asset, showing superior biological performance when compared to the current manufacturing process.
  • “This data showcases the ability of the IRO platform to provide superior biological performance, accelerate therapy development, and scale the clinical and commercial impact of these incredible therapies.

Cell and Gene Therapy Business Outlook - The Best Way to Keep up with the Growing Cell and Gene Therapy Industry - ResearchAndMarkets.com

Retrieved on: 
Venerdì, Maggio 31, 2024
Pharmaceutical, Genetics, Health, Stem Cells, Forecasting, Science, Investment, Cell, Gene, Analysis, Eye, News, CGT, Fine chemical

The new twice-monthly publication dedicated to cell and gene therapy, Cell and Gene Therapy Business Outlook will offer the following:

Key Points: 
  • The new twice-monthly publication dedicated to cell and gene therapy, Cell and Gene Therapy Business Outlook will offer the following:
    Market Sizing and Forecasting of CAGT Markets: Each issue sizes up the market opportunity and projects the future revenues for a given therapeutic segment.
  • News Briefs and Analysis of the Science That will Shape Tomorrow's Business: Cell and Gene Therapy Business Outlook is designed to provide the most relevant news.
  • Cell and Gene Therapy Business Outlook is created by market researchers and editors focused on business opportunity.
  • Each issue of Cell and Gene Therapy Business Outlook will keep track of mergers, investments, licensing, technology transfers and partnerships in the industry.

Frost & Sullivan Released Report: "The Fourth Revolutionary Wave of Biologics Manufacturing: CDMOs Empower Large-Scale Production of Biologics"

Retrieved on: 
Mercoledì, Maggio 29, 2024
Bioprocess, Stainless steel, Fourth, Bioreactor, CGT, ADC, Frost, Research, Biopharmaceutical, CDMO, Fine chemical

Shanghai, China--(Newsfile Corp. - May 29, 2024) - Frost & Sullivan released a report, titled "The Fourth Revolutionary Wave of Biologics Manufacturing: CDMOs Empower Large-Scale Production of Biologics".

Key Points: 
  • Shanghai, China--(Newsfile Corp. - May 29, 2024) - Frost & Sullivan released a report, titled "The Fourth Revolutionary Wave of Biologics Manufacturing: CDMOs Empower Large-Scale Production of Biologics".
  • The global market size of biologics CDMOs has grown significantly from US$13.3 billion in 2018 to US$29.3 billion in 2022.
  • Given the challenges in process development and production for different biologics types, specialized CDMO services for each type have emerged.
  • In the fourth revolutionary wave of biologics manufacturing, leading companies invest heavily in production capacity to remain competitive
    The world's leading CDMOs are ramping up capacities for the large-scale commercial production of biologics.

Ori Biotech Unveils IRO Platform at Annual International Society for Cell & Gene Therapy Conference

Retrieved on: 
Mercoledì, Maggio 29, 2024
Patient, Cell, Doctor of Philosophy, Ori, Biology, ISCT, Automation, Organization, International Society, CGT, CSO, Workflow, IRO, Freedom, GMP, Pharmaceutical industry

The company today revealed the IRO platform at ISCT 2024 , International Society for Cell & Gene Therapy’s 30th annual conference, in Vancouver, British Columbia.

Key Points: 
  • The company today revealed the IRO platform at ISCT 2024 , International Society for Cell & Gene Therapy’s 30th annual conference, in Vancouver, British Columbia.
  • It is estimated that more than 95% of patients are left without access to cell and gene therapies1.
  • Ori has developed the IRO platform as part of their mission to enable widespread patient access to life-saving cell and gene therapies.
  • The IRO platform automates better biology, accelerates therapy development, and enables therapy developers to scale their products' clinical and commercial impact.

Cellular Origins and Cell and Gene Therapy Catapult Collaborate to Demonstrate Universal Automation of CGT Manufacturing

Retrieved on: 
Mercoledì, Maggio 29, 2024
Technology, Research, Genetics, Health Technology, Biotechnology, Health, Robotics, Other Science, Science, Constellation, Partnership, Stevenage, MIC, Cell, Patient, Automation, Risk, TTP, FDA, CGT, Gene, Cellular, ATMP, GMP, Pharmaceutical industry

Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and the Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, today announced a collaboration to demonstrate universal automation of CGT manufacturing.

Key Points: 
  • Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and the Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, today announced a collaboration to demonstrate universal automation of CGT manufacturing.
  • The partnership will undertake the physical and digital integration of existing bioprocessing equipment at the CGT Catapult’s Stevenage Manufacturing Innovation Centre (MIC) using Cellular Origins’ robotic platform, Constellation™.
  • 2023 was a landmark year for the CGT industry, further demonstrating the growing need to scale CGT manufacturing.
  • CGT Catapult’s experience in establishing GMP facilities and optimising cell therapy manufacture is directly aligned with Cellular Origins’ mission to prove the impact automated manufacturing can have in transforming cell therapy production.

Orgenesis Provides Business Update for the First Quarter of 2024

Retrieved on: 
Martedì, Maggio 21, 2024
Security (finance), Partnership, Patient, Investment, Government, CGT, Pharmaceutical industry

(NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the first quarter ended March 31, 2024.

Key Points: 
  • (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the first quarter ended March 31, 2024.
  • Vered Caplan, CEO of Orgenesis, said, “We continue to advance the commercialization of our decentralized platform through Octomera, our strategic CGT processing subsidiary, including our Orgenesis Mobile Processing Units and Labs (OMPULs).
  • Under the agreement, Germfree will co-market Orgenesis’ decentralized Octomera services and provide us access to Germfree’s global network and customer base.
  • As a result, we plan to accelerate our go-to-market strategy with the OMPULs, while increasing our focus on our therapeutic pipeline.

Rogers Awards $1M to Canada’s Got Talent Champion REBECCA STRONG From PRINCE ALBERT, SASKATCHEWAN

Retrieved on: 
Mercoledì, Maggio 15, 2024
Mission, CIBC, Rogers Sports & Media, Friends, Emotion, Sensation, AB, OLG, Internet, Prince Albert, CGT, Dream, Human, A-Game, NS, Tears, Family, MYM, Kardinal Offishall, Film industry

TORONTO, May 14, 2024 (GLOBE NEWSWIRE) -- Canadians from coast-to-coast-to-coast casted their votes and the results are in. REBECCA STRONG from Prince Albert, Saskatchewan is the Canada’s Got Talent Season 3 champion after impressing the audience, the #CGT judges – Howie Mandel, Lilly Singh, Kardinal Offishall, Trish Stratus – and host Lindsay Ell with her captivating voice during tonight’s highly-anticipated live two-hour finale on Citytv and Citytv+.

Key Points: 
  • Thank you so much, Marsi Cho,” said Rebecca Strong, Winner, Canada’s Got Talent.
  • Together with Canada’s Got Talent, Rogers is committed to investing in diverse original Canadian stories while nurturing homegrown talent.
  • “Rogers just awarded the biggest cash prize in Canadian television history, enabling a true talent the ability to reach their potential.
  • Lilly’s Golden Buzzer REBECCA STRONG (Prince Albert, SK) stunned the audience at OLG Stage when she sang “Rolling in the Deep” by Adele.

Cell and Gene Therapy (CGT) Supply Chain Software Market - Global Industry Trends and Forecasts Till 2035 - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Maggio 23, 2024
Technology, Genetics, Transport, Health Technology, Software, Biotechnology, Health, Logistics, Supply Chain Management, Oncology, Partnership, LIMS, Cell, EMS, Capital loss, Deployment, Investment, COP, QMS, CGT, IMS, Research, Growth, Gene, PMS, LMS, Temperature, Medical device

The "Cell and Gene Therapy Supply Chain Software Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Process Component, Type of Software, Mode of Deployment, Scale of Operation, Type of End-user and Key Geographical Regions" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell and Gene Therapy Supply Chain Software Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Process Component, Type of Software, Mode of Deployment, Scale of Operation, Type of End-user and Key Geographical Regions" report has been added to ResearchAndMarkets.com's offering.
  • This research study consists of industry trends, detailed cell and gene therapy supply chain software market analysis, funding and investment trends, partnerships and collaborations analysis, platform utilization trends, stakeholder needs analysis and market impact analysis.
  • The report includes cell and gene therapy supply chain software market forecast and opportunity analysis.
  • One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential of the software developers in the cell and gene therapy supply chain software market, over the forecast period.

Matica Bio at BIO International 2024: Leading the Way in CGT Innovation and U.S. Manufacturing Strategy

Retrieved on: 
Mercoledì, Maggio 22, 2024
Biotechnology, Health, Genetics, Clinical Trials, Health Technology, Technology transfer, Shingles, ODF, NK, Government, CGT, Vaccine, Gene, BIO, Sartorius, CDMO, Fine chemical

Matica Biotechnology (Matica Bio) announced today that it will participate in the world’s largest biotech exhibition, the BIO International Convention (BIO USA).

Key Points: 
  • Matica Biotechnology (Matica Bio) announced today that it will participate in the world’s largest biotech exhibition, the BIO International Convention (BIO USA).
  • Matica Biotechnology (Matica Bio) is proud to highlight its global sites and expertise in Cell and Gene Therapy (CGT) development and manufacturing at this year's BIO International Convention.
  • As a leading CDMO, Matica Bio offers tailored services that ensure seamless CGT development and manufacturing from preclinical through clinical stages.
  • Matica Bio also collaborates with four other production facilities within the CHA Bio Group: Bundang CHA Hospital GMP, Matica Bio Labs, Cell Gene Biobank, and Matica Bio Japan.